NDLI: Clinical models and biochemical predictors of VTE in lung cancer.

Please wait, while we are loading the content...

Year: 2016 Volume: 35

Year: 2015 Volume: 34

Year: 2014 Volume: 33

Year: 2014 Volume: 33 Issue: 4

Year: 2014 Volume: 33 Issue: 1

Year: 2014 Volume: 33 Issue: 2-3

Recent progress on nutraceutical research in prostate cancer.

Androgen receptor signaling in prostate cancer.

Novel drugs targeting the androgen receptor pathway in prostate cancer.

A multi-targeted approach to treating bone metastases.

Bone-targeting agents in prostate cancer.

Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases.

Histone H2A.Z deregulation in prostate cancer. Cause or effect?

RANK-mediated signaling network and cancer metastasis.

Growth factor and signaling pathways and their relevance to prostate cancer therapeutics.

The role of epithelial plasticity in prostate cancer dissemination and treatment resistance.

Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy.

Integrating new discoveries into the 'vicious cycle' paradigm of prostate to bone metastases.

AR function in promoting metastatic prostate cancer.

Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.

Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.

Mouse models of prostate cancer: picking the best model for the question.

Promising areas of prostate cancer research.

Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel.

Immunotherapy for prostate cancer: recent developments and future challenges.

Emerging technology: applications of Raman spectroscopy for prostate cancer.

Src signaling pathways in prostate cancer.

The developing story of Sprouty and cancer.

Clinical models and biochemical predictors of VTE in lung cancer.

Immune regulation of therapy-resistant niches: emerging targets for improving anticancer drug responses.

Mimicking breast cancer-induced bone metastasis in vivo: current transplantation models and advanced humanized strategies.

Circulating tumour cells--a bona fide cause of metastatic cancer.

Advances in genomic characterization of circulating tumor cells.

Antibody-based imaging strategies for cancer.

Emerging strategies to overcome resistance to endocrine therapy for breast cancer.

Extracellular acidity, a 'reappreciated' trait of tumor environment driving malignancy: perspectives in diagnosis and therapy.

Year: 2013 Volume: 32

Year: 2012 Volume: 31

Year: 2011 Volume: 30

Year: 2010 Volume: 29

Year: 2009 Volume: 28

Clinical models and biochemical predictors of VTE in lung cancer.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Roselli, M. Riondino, S. Mariotti, S. La Farina, F. Ferroni, P. Guadagni, F.
Description	Country affiliation: Italy Author Affiliation: Roselli M ( Department of Systems Medicine, Medical Oncology, Tor Vergata Clinical Center, University of Rome 'Tor Vergata', Viale Oxford 81, 00133, Rome, Italy.)
Abstract	Venous thromboembolism (VTE) is a frequent complication of lung cancer and its treatment, especially in the advanced stages of disease. The risk of a pro-thrombotic state might increase through the activation of hemostasis, occurring both via the induction of a pro-coagulant activity and with platelet involvement, ultimately leading to the development of metastases. Despite the acknowledgement of an increased thrombophilic condition in cancer patients, and the experimental evidence that heparin compounds may have direct anticancer benefits, there is no univocal consent regarding VTE prevention in cancer outpatients receiving therapy. Thus, many authors highlighted the need for the development of stratification techniques to identify at-risk patients who might benefit from thromboprophylaxis. Clinical risk models were developed and validated, in order to assign high-risk patients to a proper thromboprophylaxis regimen that, however, might not be justified in all clusters. Besides, efforts have been devoted to identify candidate biomarkers that may be used in VTE risk assessment, although none has been recognized, so far, as a predictor for VTE in lung cancer patients. In this review, we will summarize the latest information concerning this very controversial topic, with focus on some of the proposed strategies to select the appropriate patients for prophylaxis.
File Format	HTM / HTML
ISSN	01677659
Issue Number	2-3
Volume Number	33
e-ISSN	15737233
Journal	Cancer and Metastasis Reviews
Language	English
Publisher	Springer
Publisher Date	2014-09-01
Publisher Place	Netherlands
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Neoplasms Lung Neoplasms Complications Venous Thromboembolism Diagnosis Etiology Anticoagulants Therapeutic Use Chemoprevention Disease Progression Hemostasis Humans Incidence Blood Drug Therapy Pathology Neoplasm Staging Prognosis Risk Epidemiology Prevention & Control Journal Article Research Support, Non-u.s. Gov't Review
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Clinical significance of the neutrophil-lymphocyte ratio in venous thromboembolism patients with lung cancer.

Incidence of venous thromboembolism in advanced lung cancer and efficacy and safety of direct oral anticoagulants: a multicenter, prospective, observational study (Rising-VTE/NEJ037 study)

Direct oral anticoagulants in pediatric venous thromboembolism: Experience in specialized pediatric hemostasis centers in the United States

Epidemiology and risk factors for venous thromboembolism in lung cancer.

The challenges of managing cancer related venous thromboembolism in the palliative care setting.

Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients.

Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer.

The impact of thromboprophylaxis on cancer survival: focus on pancreatic cancer.

Clinical models and biochemical predictors of VTE in lung cancer

Clinical models and biochemical predictors of VTE in lung cancer.

Similar Documents

Clinical significance of the neutrophil-lymphocyte ratio in venous thromboembolism patients with lung cancer.

Incidence of venous thromboembolism in advanced lung cancer and efficacy and safety of direct oral anticoagulants: a multicenter, prospective, observational study (Rising-VTE/NEJ037 study)

Direct oral anticoagulants in pediatric venous thromboembolism: Experience in specialized pediatric hemostasis centers in the United States

Epidemiology and risk factors for venous thromboembolism in lung cancer.

The challenges of managing cancer related venous thromboembolism in the palliative care setting.

Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients.

Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer.

The impact of thromboprophylaxis on cancer survival: focus on pancreatic cancer.

Clinical models and biochemical predictors of VTE in lung cancer

Clinical models and biochemical predictors of VTE in lung cancer.